RNAi Patent Debate' Due Later?
Novartis Tapping Alnylam; Sirna 'Sticks To Strategy'
By Randall Osborne
Monday, September 12, 2005
"We think, unquestionably, we're the leaders," said Van Miles, senior vice president of business development for Alnylam Pharmaceuticals Inc., talking last week about RNA interference.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.